The Readout Loud Podcast
1) 384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen
For this very special episode of The Readout LOUD Allison, Adam, and Elaine are live from the J.P. Morgan Healthcare Conference in San Francisco. The hosts are joined by ARCH Venture Partners co-foun...Show More
2) 383: JPM to bring more deals and happy CEOs
What news happened over the holidays? Why will pharma CEOs be greeted warmly in San Francisco next week? And who will buy Revolution Medicines? We discuss all that and more on this week’s episode of ...Show More
3) 382: Biotech's year in review
Is the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays? We discuss all that and more on this week's ep...Show More
4) 381: The future of American science and a dispatch from ASH
How did Terns Pharmaceuticals and its “hodgepodge” pipeline grab attention at the American Society of Hematology conference? Is Eli Lilly’s new drug making people lose too much weight? And what, exact...Show More
5) 380: A new top drug regulator and the future of psychedelics
On this week’s episode of "The Readout Loud": a look at an emerging class of psychedelic drugs that may treat depression, anxiety, and other psychiatric conditions without the hallucinogenic “trip.” P...Show More
6) 379: How Mark Cuban plans to ‘f— up’ health care
How much time does Mark Cuban spend thinking about health care? Why does he think TrumpRx, a direct drug purchasing platform that the Trump administration aims to launch, is “the most incredible progr...Show More
7) 378: Merck's heart disease win and the FDA's new drug regulator
What does Rick Pazdur's new role mean for the Food and Drug Administration? Has Merck solved the PCSK9 access issue? And how much credit can the president take for lowering GLP-1 drug prices? Dean Li...Show More
8) 377: Melodrama at the FDA and the Pfizer-Novo bidding war
On a jam-packed show, your co-hosts, minus the vacationing Allison DeAngelis, chat with STAT’s D.C. correspondent Lizzy Lawrence about a slow-boiling feud between Vinay Prasad, the head of the FDA’s b...Show More
9) 376: BridgeBio’s great week and Moderna’s unraveling
Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween? We discuss all that on this week’s episode of ...Show More
10) 375: Startups push the FDA and biotech booms in North Carolina
Can Trump take credit for North Carolina's booming biopharma industry? Which drugs could get a shortcut to the market? And who wore a tuxedo to the STAT Summit? We discuss all that and more in the la...Show More